Sandoz Is Covering ‘Six Of Eight’ GLP-1 Opportunities, With Plans To Evolve

Greater Free Cash Flow In Years Ahead Will Fuel Ambitions; API Supply Crucial

“I’ve never launched a drug quite like this,” Sandoz’s CEO Richard Saynor has admitted frankly, as the firm spoke about its plans to launch GLP-1 assets in the future, starting with semaglutide in markets including Canada and Brazil as early as 2026.

Growth Blue Arrow Up
• Source: Shutterstock

“We currently see eight GLP-1s assets in the market. We’re covering six of those already, and we’re going to look to add as the market is evolving,” Sandoz has revealed, as it delved deeper into what it estimates is a near $60bn loss of exclusivity opportunity in the next decade.

Speaking during the firm’s recent Sandoz Strategic Review 2024 event in Zurich, Switzerland, Sandoz’s management underlined plans in the midterm to use a partnered approach to spring up early in developed non-US, non-EU markets

More from Generics

More from Products

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By 

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.